Bausch Health Companies BHC Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Revenue by Business | |||||
| Bausch + Lomb | $5.1B+6.5% | $4.79B+15.6% | $4.15B+10.0% | $3.77B+0.1% | |
| Diversified | $937M-1.4% | $950M+0.7% | $943M-3.6% | $978M-12.8% | |
| International | $1.13B+1.9% | $1.11B+3.7% | $1.07B+8.4% | $988M-15.3% | |
| Salix | $2.58B+10.5% | $2.33B+3.7% | $2.25B+7.7% | $2.09B+0.8% | |
| Solta Medical | $518M+17.7% | $440M+26.8% | $347M+15.7% | $300M-2.6% | |
| Operating Income (Loss) by Business | |||||
| Bausch + Lomb | $1.13B+1.5% | $1.11B+13.1% | $980M+12.1% | $874M-8.8% | |
| Diversified | $627M+0.2% | $626M+6.8% | $586M-4.2% | $612M-15.2% | |
| International | $334M-11.2% | $376M+12.2% | $335M+3.4% | $324M-19.6% | |
| Salix | $1.93B+20.2% | $1.6B+3.5% | $1.55B+4.0% | $1.49B-0.3% | |
| Solta Medical | $232M+8.9% | $213M+32.3% | $161M+19.3% | $135M-19.2% | |
| SG&A by Business | |||||
| Bausch + Lomb | $1.78B+5.4% | $1.69B+20.5% | $1.4B+11.9% | $1.25B— | |
| Diversified | $169M0.0% | $169M-11.1% | $190M-10.0% | $211M— | |
| International | $236M+10.3% | $214M+4.4% | $205M+13.3% | $181M— | |
| Salix | $402M-12.2% | $458M+10.1% | $416M+14.9% | $362M— | |
| Solta Medical | $131M+19.1% | $110M+25.0% | $88M+10.0% | $80M— | |
| R&D by Business | |||||
| Bausch + Lomb | $144M+19.0% | $121M-0.8% | $122M-0.8% | $123M— | |
| Diversified | $14M-6.7% | $15M-16.7% | $18M-28.0% | $25M— | |
| International | $27M+12.5% | $24M+4.3% | $23M+4.5% | $22M— | |
| Salix | $79M-20.2% | $99M-4.8% | $104M+108% | $50M— | |
| Solta Medical | $26M+44.4% | $18M-10.0% | $20M+5.3% | $19M— | |
| Additions by Business | |||||
| Bausch + Lomb | $97M— | —— | $31M+520% | $5M— | |
| Diversified | $0— | —— | $0— | $0— | |
| International | $0— | —— | $0— | $0— | |
| Salix | $0— | —— | $0— | $0— | |
| Solta Medical | $22M— | —— | $0— | $0— | |
| Goodwill, Foreign Currency Translation, Gain (Loss) by Business | |||||
| Bausch + Lomb | -$148M-283% | $81M+319% | -$37M+51.9% | -$77M0.0% | |
| International | -$110M— | —— | —— | -$36M+41.9% | |
| Salix | $0— | $0— | $0— | —— | |
| Solta Medical | $0— | $0— | $0— | —— | |
| Goodwill by Business | |||||
| Bausch + Lomb | $21.61B+2.2% | $21.15B+0.1% | $21.12B+0.9% | $20.92B-2.1% | |
| Diversified | $6.78B-2.9% | $6.98B-13.2% | $8.04B— | —— | |
| International | $3.51B+5.4% | $3.33B0.0% | $3.33B+7.4% | $3.1B-7.9% | |
| Salix | $12.64B0.0% | $12.64B0.0% | $12.64B0.0% | $12.64B0.0% | |
| Solta Medical | $482M+4.8% | $460M0.0% | $460M0.0% | $460M— | |
| Goodwill, impairment loss by Business | |||||
| Bausch + Lomb | $0— | —— | —— | —— | |
| Diversified | $145M— | —— | —— | $824M— | |
| International | $0— | —— | —— | —— | |
| Salix | $0— | —— | —— | —— | |
| Solta Medical | $0— | —— | —— | —— | |
| Revenue by Product | |||||
| Other revenues | $110M+2.8% | $107M+13.8% | $94M-5.1% | $99M-6.6% | |
| Price Appreciation Credit | $18M0.0% | $18M+63.6% | $11M+10.0% | $10M— | |
| Product sales | $10.16B+6.7% | $9.52B+9.9% | $8.66B+8.0% | $8.03B-3.6% | |
| Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues by Product | |||||
| Other revenues | $64M+20.8% | $53M+32.5% | $40M-16.7% | $48M+9.1% | |
| Product sales | $2.95B+8.1% | $2.73B+8.3% | $2.52B+8.8% | $2.32B-1.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Bausch Health Companies break its business down?
- Bausch Health Companies (BHC) reports revenue by business across 5 parts — Bausch + Lomb, Diversified, International, Salix and Solta Medical. Each is extracted from the segment footnotes and tracked over time.
- Where does Bausch Health Companies's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Bausch Health Companies's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.